

Reference:	FOI.20100.26
Subject:	Asthma treatments
Date of Request:	2 April 2026

Requested:

1. How many patients have been treated (for any condition) in the last 4 months with:
 - Benralizumab
 - Dupilumab
 - Omalizumab
 - Reslizumab
 - Mepolizumab
 - Tezepelumab

2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:
 - Age 6-11
 - Age 12-17
 - Age 18 and above

3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:
 - Dupilumab
 - Omalizumab

4. How many patients have been treated in the last 4 months for Chronic Obstructive Pulmonary Disease (COPD) with:
 - Dupilumab
 - Mepolizumab

5. How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year?
 - a. Of these patients, how many have been treated in the last 4 months with:
 - Benralizumab
 - Dupilumab
 - Omalizumab
 - Reslizumab
 - Mepolizumab
 - Tezepelumab

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of patients that have been treated within Secondary Care for any condition, with the listed medications, during the period 1 December 2025 to 31 March 2026.

Medication	Number
Benralizumab	100
Dupilumab	167
Omalizumab	20
Reslizumab	0
Mepolizumab	28
Tezepelumab	155

2. The UHB provides within the table below, the number of patients that received the medications detailed in question 1 within Secondary Care, by the age ranges listed, during the period 1 December 2025 to 31 March 2026.

Age range	Number
6 to 11	9
12 to 17	15
18 and over	443

3. The UHB provides within the table below, the number of respiratory patients that have been treated within Secondary Care with the listed medications, during the period 1 December 2025 to 31 March 2026.

Medication	Number
Dupilumab	14
Omalizumab	*

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller

4. The UHB confirms that it has no patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) recorded as receiving the listed medications, during the period 1 December 2025 to 31 March 2026.
5. The UHB confirms that eight (8) patients have been diagnosed with both chronic sinusitis and nasal polyps, as recorded on the UHB's Welsh Patient Administration System (WPAS), during the 2025/26 financial year.
- a. The UHB confirms that no patients diagnosed with both chronic sinusitis and nasal polyps have received the listed medications, during the period 1 December 2025 to 31 March 2026.

